JP2011514349A - フルベストラント配合物 - Google Patents
フルベストラント配合物 Download PDFInfo
- Publication number
- JP2011514349A JP2011514349A JP2010549670A JP2010549670A JP2011514349A JP 2011514349 A JP2011514349 A JP 2011514349A JP 2010549670 A JP2010549670 A JP 2010549670A JP 2010549670 A JP2010549670 A JP 2010549670A JP 2011514349 A JP2011514349 A JP 2011514349A
- Authority
- JP
- Japan
- Prior art keywords
- poloxamer
- formulation
- fulvestrant
- polyethylene glycol
- dihydrolipoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title claims abstract description 142
- 239000000203 mixture Substances 0.000 title claims abstract description 130
- 229960002258 fulvestrant Drugs 0.000 title claims abstract description 127
- 238000009472 formulation Methods 0.000 title claims abstract description 107
- 239000004359 castor oil Substances 0.000 claims abstract description 55
- 235000019438 castor oil Nutrition 0.000 claims abstract description 55
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 55
- 238000010255 intramuscular injection Methods 0.000 claims abstract description 20
- 239000007927 intramuscular injection Substances 0.000 claims abstract description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 249
- 229920001983 poloxamer Polymers 0.000 claims description 187
- 229960000502 poloxamer Drugs 0.000 claims description 167
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 165
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 claims description 99
- 239000002202 Polyethylene glycol Substances 0.000 claims description 90
- 229920001223 polyethylene glycol Polymers 0.000 claims description 90
- 239000002904 solvent Substances 0.000 claims description 64
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 claims description 33
- 238000002347 injection Methods 0.000 claims description 29
- 239000007924 injection Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 17
- 229940087861 faslodex Drugs 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 13
- 235000006708 antioxidants Nutrition 0.000 claims description 13
- 230000007794 irritation Effects 0.000 claims description 12
- 230000003078 antioxidant effect Effects 0.000 claims description 10
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 10
- 235000019136 lipoic acid Nutrition 0.000 claims description 10
- 229960002663 thioctic acid Drugs 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 9
- 230000015556 catabolic process Effects 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 239000006184 cosolvent Substances 0.000 claims description 5
- 239000003981 vehicle Substances 0.000 claims description 5
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 4
- 229920001993 poloxamer 188 Polymers 0.000 claims description 4
- 239000011877 solvent mixture Substances 0.000 claims description 4
- 229940044519 poloxamer 188 Drugs 0.000 claims description 3
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 231100000957 no side effect Toxicity 0.000 claims description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 2
- 239000000473 propyl gallate Substances 0.000 claims description 2
- 229940075579 propyl gallate Drugs 0.000 claims description 2
- 235000010388 propyl gallate Nutrition 0.000 claims description 2
- VIMFRQPQNUFOEQ-UHFFFAOYSA-M sodium;hydrogen sulfate;propan-2-one Chemical compound [Na+].CC(C)=O.OS([O-])(=O)=O VIMFRQPQNUFOEQ-UHFFFAOYSA-M 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 230000000052 comparative effect Effects 0.000 claims 1
- QUXJSCAOGVQXNK-UHFFFAOYSA-N formaldehyde;sodium;sulfanediol Chemical compound [Na].O=C.OSO QUXJSCAOGVQXNK-UHFFFAOYSA-N 0.000 claims 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 claims 1
- 229940085675 polyethylene glycol 800 Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 description 30
- 239000000047 product Substances 0.000 description 21
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 18
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000007857 degradation product Substances 0.000 description 5
- 238000010525 oxidative degradation reaction Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229940066675 ricinoleate Drugs 0.000 description 5
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 229960002903 benzyl benzoate Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 239000012457 nonaqueous media Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022079 Injection site irritation Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HRKQOINLCJTGBK-UHFFFAOYSA-N dihydroxidosulfur Chemical compound OSO HRKQOINLCJTGBK-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- ISXSFOPKZQZDAO-UHFFFAOYSA-N formaldehyde;sodium Chemical compound [Na].O=C ISXSFOPKZQZDAO-UHFFFAOYSA-N 0.000 description 1
- 229940027974 fulvestrant 50 mg/ml Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940100530 zinc ricinoleate Drugs 0.000 description 1
- GAWWVVGZMLGEIW-GNNYBVKZSA-L zinc ricinoleate Chemical compound [Zn+2].CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O.CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O GAWWVVGZMLGEIW-GNNYBVKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6856008P | 2008-03-07 | 2008-03-07 | |
| PCT/US2009/001437 WO2009111057A2 (en) | 2008-03-07 | 2009-03-05 | Fulvestrant formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011514349A true JP2011514349A (ja) | 2011-05-06 |
| JP2011514349A5 JP2011514349A5 (enExample) | 2012-04-19 |
Family
ID=41054291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010549670A Pending JP2011514349A (ja) | 2008-03-07 | 2009-03-05 | フルベストラント配合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (7) | US9180088B2 (enExample) |
| EP (1) | EP2249839A4 (enExample) |
| JP (1) | JP2011514349A (enExample) |
| KR (1) | KR20100121505A (enExample) |
| CN (1) | CN102014925B (enExample) |
| CA (1) | CA2716576A1 (enExample) |
| WO (1) | WO2009111057A2 (enExample) |
| ZA (1) | ZA201006315B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017208847A1 (ja) * | 2016-05-31 | 2017-12-07 | 富士フイルム株式会社 | 医薬組成物 |
| JP2019516789A (ja) * | 2016-05-06 | 2019-06-20 | イーグル ファーマスーティカルズ、インク． | フルベストラント配合物およびその使用方法 |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101677987A (zh) * | 2007-06-22 | 2010-03-24 | 赛多斯有限责任公司 | 不含吐温80的多西他赛的增溶制剂 |
| JP2011514349A (ja) | 2008-03-07 | 2011-05-06 | サイドース・エルエルシー | フルベストラント配合物 |
| US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
| US8476310B2 (en) | 2009-10-19 | 2013-07-02 | Scidose Llc | Docetaxel formulations with lipoic acid |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
| US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
| JP4929423B2 (ja) | 2010-07-22 | 2012-05-09 | 日本碍子株式会社 | 成形体、及び、成形体の製造方法 |
| CA2836831C (en) | 2011-05-20 | 2015-06-02 | Capital, Business Y Gestion De Finanzas S.L. | Pharmaceutical composition |
| CN102600064A (zh) * | 2012-03-31 | 2012-07-25 | 西安力邦制药有限公司 | 氟维司群或其衍生物缓释制剂及其制备方法 |
| CN102600073B (zh) * | 2012-03-31 | 2014-01-01 | 莱普德制药有限公司 | 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法 |
| CN102600065B (zh) * | 2012-03-31 | 2014-08-13 | 莱普德制药有限公司 | 一种氟维司群或其衍生物油性制剂及其制备方法 |
| US11179468B2 (en) | 2012-04-09 | 2021-11-23 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations |
| CA2869377C (en) * | 2012-04-09 | 2022-11-08 | Scidose, Llc | Fulvestrant formulations |
| US20160060288A1 (en) * | 2013-04-18 | 2016-03-03 | Xi'anlibang Pharmaceutical Technology Co., Ltd. | Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof |
| HUP1300646A2 (en) * | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| US9271990B2 (en) | 2014-02-14 | 2016-03-01 | Fresenius Kabi Usa, Llc | Fulvestrant formulations |
| CN107789320B (zh) * | 2016-08-31 | 2021-06-22 | 鲁南制药集团股份有限公司 | 一种氟维司群缓释注射液及其制备工艺 |
| CA3032912A1 (en) * | 2017-05-23 | 2018-11-29 | Kashiv Biosciences, Llc | High-concentration fulvestrant compositions |
| BR112020009141A2 (pt) * | 2017-11-08 | 2020-10-27 | Eagle Pharmaceuticals, Inc. | método para tratar câncer de mama num indivíduo |
| KR20220079472A (ko) * | 2020-12-04 | 2022-06-13 | 주식회사 삼양홀딩스 | 풀베스트란트의 서방형 약학 조성물 및 그 제조 방법 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997021440A1 (en) * | 1995-12-12 | 1997-06-19 | Zeneca Limited | A solution for oral administration containing ici 182,780 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2087721B (en) * | 1980-11-20 | 1984-01-25 | Beecham Group Ltd | Injectable antibiotic formulations stabilised with glycofurol |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| DE3406497A1 (de) | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung |
| US5462726A (en) | 1993-12-17 | 1995-10-31 | Bristol-Myers Squibb Company | Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents |
| US20060264357A1 (en) | 1997-04-22 | 2006-11-23 | Zikria Bashir A | Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals |
| DK0999838T3 (da) | 1997-07-29 | 2002-07-08 | Upjohn Co | Selv-emulgerende formulering for lipofile forbindelser |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| KR20020013174A (ko) | 2000-08-11 | 2002-02-20 | 민경윤 | 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물 |
| EP1345589B1 (en) | 2000-11-29 | 2007-06-27 | Lyotropic Therapeutics, Inc. | Solvent systems for pharmaceutical agents |
| US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| EP1258243A1 (en) | 2001-05-16 | 2002-11-20 | N.V. Nutricia | Lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy |
| GB0116620D0 (en) | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| US20040047835A1 (en) * | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
| AU2004265238A1 (en) | 2003-06-11 | 2005-02-24 | Novacea, Inc. | Treatment of lung cancer with active vitamin D compounds in combination with other treatments |
| CA2530407A1 (en) | 2003-07-23 | 2005-02-03 | The Regents Of The University Of California | Penetration enhancer combinations for transdermal delivery |
| US20050090551A1 (en) | 2003-10-27 | 2005-04-28 | Board Of Trustees Of Southern Illinois University | Therapeutic use of methionine for the treatment or prevention of mucositis |
| US20060003002A1 (en) | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| KR20050099311A (ko) | 2004-04-09 | 2005-10-13 | 에이엔에이치 케어연구소(주) | 주사제용 항암제 조성물 |
| WO2006037031A2 (en) * | 2004-09-27 | 2006-04-06 | Valentis, Inc. | Formulations and methods for treatment of inflammatory diseases |
| MX2007009748A (es) | 2005-02-14 | 2007-09-26 | Univ Florida State Res Found | Composiciones de taxano sustituidas con esteres ciclopropilicos en c10. |
| GB0517092D0 (en) | 2005-08-19 | 2005-09-28 | Novartis Ag | New compositions containing taxane derivatives |
| SG165404A1 (en) * | 2005-09-26 | 2010-10-28 | Hospira Australia Pty Ltd | Fulvestrant formulation |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US8338416B2 (en) | 2006-03-16 | 2012-12-25 | Pharmacylics, Inc. | Indole derivatives as inhibitors of histone deacetylase |
| US20100098735A1 (en) | 2006-10-05 | 2010-04-22 | Rajesh Jain | Injectable depot compositions and its process of preparation |
| CN101677987A (zh) | 2007-06-22 | 2010-03-24 | 赛多斯有限责任公司 | 不含吐温80的多西他赛的增溶制剂 |
| US20090181068A1 (en) | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| US8586625B2 (en) | 2008-01-16 | 2013-11-19 | Anwar Rayan | Derivatives of taxol and closely related compounds |
| JP2011514349A (ja) | 2008-03-07 | 2011-05-06 | サイドース・エルエルシー | フルベストラント配合物 |
| EP2276755A4 (en) | 2008-03-31 | 2011-05-04 | Univ Florida State Res Found | C (10) -ETHYESTER- AND C (10) -CYCLOPROPYLESTER-SUBSTITUTED TAXANES |
| KR20100018741A (ko) | 2008-08-07 | 2010-02-18 | 신풍제약주식회사 | 도세탁셀 함유 항암용 주사제 조성물 |
-
2009
- 2009-03-05 JP JP2010549670A patent/JP2011514349A/ja active Pending
- 2009-03-05 KR KR1020107019942A patent/KR20100121505A/ko not_active Withdrawn
- 2009-03-05 CN CN2009801081573A patent/CN102014925B/zh not_active Expired - Fee Related
- 2009-03-05 EP EP09716692.0A patent/EP2249839A4/en not_active Withdrawn
- 2009-03-05 WO PCT/US2009/001437 patent/WO2009111057A2/en not_active Ceased
- 2009-03-05 US US12/380,968 patent/US9180088B2/en active Active
- 2009-03-05 CA CA2716576A patent/CA2716576A1/en not_active Abandoned
-
2010
- 2010-09-02 ZA ZA2010/06315A patent/ZA201006315B/en unknown
-
2015
- 2015-11-06 US US14/934,428 patent/US9801892B2/en active Active
-
2017
- 2017-10-20 US US15/789,267 patent/US10363259B2/en active Active
-
2019
- 2019-07-11 US US16/508,741 patent/US20200188411A1/en not_active Abandoned
-
2020
- 2020-09-16 US US17/022,574 patent/US20210260076A1/en not_active Abandoned
-
2022
- 2022-08-15 US US17/819,726 patent/US20220387446A1/en not_active Abandoned
-
2023
- 2023-11-10 US US18/506,633 patent/US20240082264A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997021440A1 (en) * | 1995-12-12 | 1997-06-19 | Zeneca Limited | A solution for oral administration containing ici 182,780 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019516789A (ja) * | 2016-05-06 | 2019-06-20 | イーグル ファーマスーティカルズ、インク． | フルベストラント配合物およびその使用方法 |
| WO2017208847A1 (ja) * | 2016-05-31 | 2017-12-07 | 富士フイルム株式会社 | 医薬組成物 |
| JPWO2017208847A1 (ja) * | 2016-05-31 | 2019-01-24 | 富士フイルム株式会社 | 医薬組成物 |
| US10668083B2 (en) | 2016-05-31 | 2020-06-02 | Fujifilm Corporation | Pharmaceutical composition |
Also Published As
| Publication number | Publication date |
|---|---|
| US10363259B2 (en) | 2019-07-30 |
| US20220387446A1 (en) | 2022-12-08 |
| US20180289722A1 (en) | 2018-10-11 |
| US20240082264A1 (en) | 2024-03-14 |
| US20160058773A1 (en) | 2016-03-03 |
| EP2249839A2 (en) | 2010-11-17 |
| US20090227549A1 (en) | 2009-09-10 |
| WO2009111057A2 (en) | 2009-09-11 |
| CN102014925B (zh) | 2013-02-06 |
| CN102014925A (zh) | 2011-04-13 |
| US20200188411A1 (en) | 2020-06-18 |
| KR20100121505A (ko) | 2010-11-17 |
| EP2249839A4 (en) | 2013-10-16 |
| US20210260076A1 (en) | 2021-08-26 |
| WO2009111057A3 (en) | 2010-03-04 |
| ZA201006315B (en) | 2012-02-29 |
| WO2009111057A4 (en) | 2010-04-29 |
| CA2716576A1 (en) | 2009-09-11 |
| US9180088B2 (en) | 2015-11-10 |
| US9801892B2 (en) | 2017-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10363259B2 (en) | Fulvestrant formulations | |
| MXPA02006698A (es) | Formulacion de fulvestrant. | |
| JP7752051B2 (ja) | 長時間作用型注射用製剤およびその使用 | |
| CA2713199C (en) | Topical formulation | |
| JP2009509942A (ja) | フルベストラント製剤 | |
| JP2006522011A (ja) | 安定なカルプロフェン組成物 | |
| EP2836199A1 (en) | Fulvestrant formulations | |
| EP3664800B1 (en) | Therapeutic formulations comprising cox-2 inhibitor and uses thereof | |
| JP2018530597A (ja) | フルベストラント組成物 | |
| RU2618462C2 (ru) | Способ и улучшенная фармацевтическая композиция для ускорения трансдермальной доставки ингибитора pde-5 | |
| EP4233854A2 (en) | Therapeutic formulations and uses thereof | |
| HK40101332A (en) | Therapeutic formulations and uses thereof | |
| HK40112276A (en) | Therapeutic formulations and uses thereof | |
| ZA200400079B (en) | Pharmaceutical formulation for the intramuscular administration of fulvestrant. | |
| HK40027580B (en) | Therapeutic formulations comprising cox-2 inhibitor and uses thereof | |
| HK40027580A (en) | Therapeutic formulations comprising cox-2 inhibitor and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120302 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120302 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130806 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20130926 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130926 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140107 |